On June 1, a fundamental shift in the operational architecture of the President’s Emergency Plan for AIDS Relief (PEPFAR) took effect, marking the most significant disruption to U.S. global health diplomacy in over two decades. The policy change, part of the Trump Administration’s "America First Global Health Strategy," moves the program away from a model of integrated, U.S.-led technical assistance toward an à la carte procurement system.
Public health experts, including eight former directors of the Centers for Disease Control and Prevention (CDC), warn that this pivot risks more than just HIV/AIDS outcomes; it threatens to dismantle the very infrastructure that protects the United States from future pandemics.
A Paradigm Shift: From Partnership to Procurement
For over twenty years, PEPFAR has served as the crown jewel of American soft power. Launched in 2003, the program has been credited with saving over 26 million lives and preventing millions of HIV infections. Historically, the U.S. State Department allocated Congress-appropriated funds to the CDC, which provided technical expertise, laboratory support, and disease surveillance training to partner nations.
Under the new "America First" guidance, this model is being replaced by a transactional framework. Foreign nations are now expected to choose which services they wish to "purchase" from the CDC. While countries receiving over $125 million in U.S. aid are mandated to acquire a "minimum package" of services, the flexibility once afforded to the CDC to deploy experts and resources based on clinical and epidemiological necessity is being severely curtailed.
The State Department’s policy document argues that this shift is designed to break a "culture of dependency" within recipient nations. However, critics have noted a more strategic, albeit controversial, ambition embedded in the text: the potential to leverage foreign health assistance to secure access to essential resources, such as rare earth minerals and other raw materials, effectively tethering public health outcomes to geopolitical and economic extraction.
The Financial Cliff: A 93% Reduction?
The most immediate concern for public health officials is the projected cratering of the CDC’s global budget. Historically, the CDC has received approximately $2 billion annually in PEPFAR funding to sustain its global health security outposts.
Dr. Tom Frieden, who served as CDC director from 2009 to 2017 and is currently the president and CEO of the nonprofit Resolve to Save Lives, paints a grim picture of the fiscal fallout. According to projections, the funding earmarked for the CDC could plummet to as low as $150 million—a staggering 93% reduction from fiscal year 2025 levels.
"The underlying concept is a good one, with countries deciding what services they want partnership on and with which partners," Frieden told MedPage Today. "But the reality is that you cannot order off a menu if the restaurant is closed. This approach would effectively end the CDC’s ability to support partner countries and, by extension, protect Americans."
Chronology of the Crisis
The unfolding crisis can be traced through a series of key milestones that have led to the current state of uncertainty:
- 2003: George W. Bush signs the PEPFAR legislation, beginning a bipartisan era of unprecedented global health investment.
- Early 2026: The second Trump Administration identifies foreign aid and international health programs, including PEPFAR and USAID, as primary targets for budget consolidation.
- May 2026: Emily Bass, a prominent AIDS activist and author, publishes the details of the State Department’s "America First Global Health Strategy" on her Substack, exposing the plan to shift to an à la carte model.
- Late May 2026: Eight former CDC directors publish an op-ed in STAT, warning that the transition lacks a manageable timeline and threatens the closure of 18 global outposts.
- June 1, 2026: The new operational guidance for PEPFAR officially takes effect.
- June 2026: Dr. Tom Frieden alerts the public during a MedPage Today webinar that the government has already halted the work of over 100 organizations providing HIV care to more than 8 million patients.
The Ripple Effect: Beyond HIV/AIDS
While the political debate often centers on HIV, the practical implications are far broader. Dr. Frieden has emphasized repeatedly that "PEPFAR’s global impact is bigger than HIV." The infrastructure built for PEPFAR—laboratories designed to track viral loads, supply chains optimized for antiretroviral delivery, and trained epidemiological workforces—serves as the backbone for responding to other deadly pathogens.
When a country loses its PEPFAR-funded lab capacity, it loses the ability to detect emerging threats like Ebola, Marburg, or novel influenza strains. The supply chains that move HIV medication are the same ones used to distribute vaccines and treatments for other health emergencies.
"We are letting our guard down," Frieden warned. "The ongoing outbreaks of hantavirus and Ebola are serious, but they are localized. The next outbreak could be global, and if we have dismantled our eyes and ears on the ground, we will not know it is coming until it is too late."
Professional and Political Implications
The human cost of this transition is expected to be significant. With only three months remaining in the 2026 fiscal year, the CDC is faced with the logistical nightmare of repatriating more than 100 doctors, epidemiologists, and laboratory experts. The cost of such a withdrawal, both in financial terms and in the loss of decades-long diplomatic relationships, is difficult to quantify but likely to be irreversible.
Former CDC directors, in their STAT op-ed, underscored that the speed of this transition is the most dangerous element. "Without a transition plan and a manageable timeline, the result will not be a more effective PEPFAR—it will be the rapid dismantling of America’s overseas public health capability."
Official Responses and the Divergent Reality
The U.S. State Department maintains that the concerns regarding the closure of outposts are overstated. In a statement provided to MedPage Today, a spokesperson claimed the Department is "committed to ensuring continued funding for 100% of Americans employed overseas through PEPFAR funding" and that they were "not aware of any such closures."
The Department further argued that the CDC remains a vital partner, asserting that many global health security services—including disease surveillance and biosafety training—remain "essential to successful HIV programs and to protecting U.S. national security."
However, the State Department remained silent when pressed on whether the June 1 plan would undergo modifications or if the fiscal realities described by the former CDC directors would be addressed. The disconnect between the Department’s assurances and the operational realities on the ground suggests a significant breakdown in communication or a fundamental disagreement regarding the viability of the new procurement-based model.
Conclusion: A Precarious Future
As the international community watches, the future of the world’s most successful public health program hangs in the balance. The push for "America First" efficiency, while perhaps intended to modernize a bloated system, risks eroding the very tools that have prevented the world from sliding into a pandemic state for over two decades.
Without a pivot toward a more collaborative, multi-year transition plan—one that prioritizes scientific partnership over market-based transactions—the United States risks losing its position as the global leader in health security. As experts continue to caution, the infrastructure of global health is not something that can be easily dismantled and rebuilt; once the connections are severed and the experts are brought home, the cost of re-establishing that trust and capability may prove to be far higher than the funds saved by the current policy.
